# EDGAR Filing Document

**Accession Number:** 0001739174
**File Stem:** 0001213900-23-001398
**Filing Date:** 2023-1
**Character Count:** 4908
**Document Hash:** fe01356d88a94d9784be2654f5915aa7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001398.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001213900-23-001398

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230105

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BiomX Inc.
- **CENTRAL INDEX KEY:** 0001739174
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38762
- **FILM NUMBER:** 23515441

**BUSINESS ADDRESS:**
- **STREET 1:** 22 EINSTEIN ST., 4TH FLOOR
- **CITY:** NESS ZIONA
- **STATE:** L3
- **ZIP:** 7414003
- **BUSINESS PHONE:** (972) 72 394 2377

**MAIL ADDRESS:**
- **STREET 1:** 22 EINSTEIN ST., 4TH FLOOR
- **CITY:** NESS ZIONA
- **STATE:** L3
- **ZIP:** 7414003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chardan Healthcare Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180430

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): January 6, 2023 (**January 5, 2023**)

---

| |
|:---|
| **BiomX Inc.** |
| (Exact Name of Registrant as Specified in its Charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38762** | **82-3364020** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **22 Einstein St., Floor 4<br> Ness Ziona, Israel** | **7414003** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(972) 72-394-2377**

---

| |
|:---|
| **n/a** |
| (Former name or former address, if changed since last report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class**<br>| **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one share of Common Stock\ and one Warrant entitling the holder to receive one half share of Common Stock<br>| PHGE.U | NYSE American |
| Common Stock, $0.0001 par value<br>| PHGE | NYSE American |
| Warrants, each exercisable for one-half of a share of Common Stock, at an exercise price of $11.50 per share<br>| PHGE.WS | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 **Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**

On January 5, 2023, Jonas Grossman and Dr. Gbola Amusa each resigned from the Board of Directors (the "Board") of BiomX Inc. (the "Company"), for personal reasons, effective immediately. Mr. Grossman and Dr. Amusa did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company is actively seeking new candidates to fill the vacancies on the Board.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BIOMX INC.** | **BIOMX INC.** |
| January 6, 2023 | By: | /s/ Jonathan Solomon |
|  |  | Name: Jonathan Solomon |
|  |  | Title: Chief Executive Officer |

---